Cassava Sciences Files 8-K
Ticker: FLNA · Form: 8-K · Filed: Oct 8, 2024 · CIK: 1069530
| Field | Detail |
|---|---|
| Company | Cassava Sciences INC (FLNA) |
| Form Type | 8-K |
| Filed Date | Oct 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, filing
TL;DR
Cassava Sciences filed an 8-K on Oct 8, 2024, for disclosures and exhibits. No major news.
AI Summary
Cassava Sciences, Inc. filed an 8-K on October 8, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the reporting of these items.
Why It Matters
This filing indicates Cassava Sciences is providing updated disclosures and financial information to the SEC, which is standard practice for public companies.
Risk Assessment
Risk Level: low — The filing is a routine disclosure and does not appear to contain any new material adverse information.
Key Players & Entities
- Cassava Sciences, Inc. (company) — Registrant
- 0001437749-24-030845 (document_id) — Accession Number
- October 8, 2024 (date) — Filing Date
FAQ
What is the primary purpose of this 8-K filing by Cassava Sciences?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
On what date was this 8-K filing made?
This 8-K filing was made on October 8, 2024.
What is the Commission File Number for Cassava Sciences?
The Commission File Number for Cassava Sciences is 001-41905.
What is the principal executive office address for Cassava Sciences?
The principal executive office address for Cassava Sciences is 6801 N Capital of Texas Highway, Building 1; Suite 300, Austin, Texas 78731.
Does this filing report any specific new financial results or material events?
This filing does not appear to report specific new financial results or material events beyond the disclosure of financial statements and exhibits and a Regulation FD disclosure.
Filing Stats: 537 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-10-08 08:10:49
Key Financial Figures
- $0.001 — ge on which registered Common Stock , $0.001 par value SAVA Nasdaq Capital Market
Filing Documents
- sava20241007_8k.htm (8-K) — 25KB
- ex_730551.htm (EX-99.1) — 22KB
- largelogo.jpg (GRAPHIC) — 30KB
- 0001437749-24-030845.txt ( ) — 228KB
- sava-20241008.xsd (EX-101.SCH) — 3KB
- sava-20241008_def.xml (EX-101.DEF) — 12KB
- sava-20241008_lab.xml (EX-101.LAB) — 15KB
- sava-20241008_pre.xml (EX-101.PRE) — 12KB
- sava20241007_8k_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure On October 8, 2024, Rick Barry, President and Chief Executive Officer of Cassava Sciences, Inc., issued An Open Letter to the Cassava Community. A copy of the letter is attached as Exhibit 99.1 hereto and incorporated into this Item 7.01 by reference. The information furnished in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed to be "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of such section, nor shall such information be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. 9.01: Financial Statements and Exhibits Exhibit No. Description 99.1 An Open Letter to the Cassava Community from Rick Barry, issued October 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CASSAVA SCIENCES, INC. a Delaware corporation Date: October 8, 2024 By: /s/ ERIC J. SCHOEN Eric J. Schoen Chief Financial Officer